Here is what the science shows about PRMT3 and why it matters for patients.
The Protein That Does Too Much
PRMT3 is a type of enzyme. Think of enzymes as tiny workers inside your cells. Their job is to modify other proteins, adding small chemical tags that change how those proteins behave.
Normally, PRMT3 helps with basic cell housekeeping. It helps make ribosomes, which are the protein-building machines inside every cell.
But in cancer cells, PRMT3 goes into overdrive. It starts modifying proteins it should not touch. And that changes everything.
Think of it like a lock and key system. PRMT3 acts like a key that fits many different locks. When it turns those locks, it can open doors that should stay closed. Doors that let cancer grow, spread, and survive.
How PRMT3 Helps Cancer Thrive
Scientists reviewed dozens of studies on PRMT3 and cancer. They found that this protein is overactive in at least six different cancer types. These include liver cancer, colorectal cancer, breast cancer, pancreatic cancer, lung cancer, and brain cancer.
PRMT3 does three main things that help tumors.
First, it changes how cancer cells use energy. Healthy cells burn energy slowly and carefully. Cancer cells are greedy. They burn through sugar at a frantic pace. This is called the Warburg effect. PRMT3 helps turn on this fast-burning mode, giving tumors the fuel they need to grow.
Second, PRMT3 helps cancer hide from your immune system. Your immune cells are supposed to find and destroy abnormal cells. But PRMT3 can boost a protein called PD-L1 on the surface of cancer cells. This acts like a "do not eat me" sign. It tells your immune system to back off.
Third, PRMT3 helps cancer resist chemotherapy drugs. It stabilizes certain messenger molecules inside the cell. These molecules tell the cancer to keep growing even when drugs try to stop it.
The review, published in Frontiers in Medicine in May 2026, looked at all available studies on PRMT3 in cancer. The researchers mapped out every way this protein seems to help tumors.
They found that PRMT3 modifies RNA-binding proteins. These are proteins that control which genes get turned on or off. By changing these controllers, PRMT3 can reshape the entire behavior of a cancer cell.
The protein also affects something called the cGAS-STING pathway. This is an alarm system inside cells that detects danger and calls for immune help. PRMT3 may help cancer cells silence this alarm.
But here is the catch. Most of this research was done in lab dishes and animal models. Not in human patients yet.
Right now, there are no drugs that target PRMT3. No pills you can ask your doctor about. No clinical trials open for patients.
But that could change. Scientists are now studying PRMT3 as a potential target for new cancer treatments. The idea is simple. If you can block PRMT3, you might be able to slow cancer growth, make it visible to the immune system again, and prevent drug resistance.
This is still early stage research. The studies so far show that PRMT3 plays a role in many cancers. But they also show that its effects depend on the type of cancer and the specific genetic makeup of the tumor.
Some cancers may rely heavily on PRMT3. Others may not. More research is needed to figure out which patients would benefit most from a drug that blocks this protein.
The Limits of What We Know
This review is a summary of existing studies. It does not report new experiments on patients. Most of the evidence comes from lab research and animal models.
That means we do not yet know if blocking PRMT3 will work safely in humans. Proteins like PRMT3 also have normal jobs in healthy cells. Blocking them could cause side effects.
The researchers are careful to call PRMT3 a "context-dependent" regulator. That is a fancy way of saying it matters in some situations but not others. Finding the right situations will take time.
What Happens Next
The next step is for scientists to develop drugs that can block PRMT3. Then they need to test those drugs in lab models, then in animals, and finally in human clinical trials.
This process takes years. Sometimes a decade or more. Many promising targets never make it to patients.
But the research on PRMT3 gives scientists a clear direction. They now know which pathways to study. They know which cancers to focus on first. And they have a better understanding of how to design drugs that might work.
For patients and families facing cancer today, this news offers hope for the future. Not for tomorrow. But for a time when doctors may have one more tool to fight this disease.